SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/17.01.25

SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/17.01.25 Stock

DE000SQ86UD4

Market Closed - Deutsche Boerse AG 15:49:28 2024-06-24 EDT
0.011 ^EUR	-8.33%

Current month	+37.50%
3 months	-87.21%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/65/0.1/17.01.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab	06-24	AQ
Bristol Myers: accelerated approval in colorectal cancer	06-24	CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	06-21	BU
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	06-21	CI

More news

Quotes 5-day view

Date	Price	Change
24-06-24	0.011	-8.33%
24-06-21	0.012	+20.00%
24-06-20	0.01	+42.86%
24-06-19	0.007	0.00%
24-06-18	0.007	-30.00%

Delayed Quote Deutsche Boerse AG

Last update June 24, 2024 at 03:49 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SQ86UD
ISIN	DE000SQ86UD4
Date issued	2023-02-16
Strike	65 $
Maturity	2025-01-17 (207 Days)
Parity	10 : 1
Emission price	1.41 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.33 €
Lowest since issue	0.006 €
Delta	0.04x
Omega	10.77
Premium	54.33x
Gearing	245.84x
Moneyness	0.6497
Difference Strike	22.77 $
Difference Strike %	+35.03%
Spread	0.01 €
Spread %	47.62%
Intrinsic value	0.000000

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

42.23 USD

Average target price

53.19 USD

Spread / Average Target

+25.96%

Consensus